Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2022 (period ended September 30, 2022), upgrading reported and core forecasts and free cash flow outlook for the fiscal year and reconfirming Management Guidance for core growth at constant exchange rate (CER).

Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast

Alnylam Pharmaceuticals

Amgen

BioCryst Pharmaceuticals

Beam Therapeutics

CRISPR Therapeutics

Graphite Bio

Ionis Pharma

Intellia Therapeutics

Pfizer

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

OSAKA, Japan & FREIBURG, Germany & DARMSTADT, Germany--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK), Zedira and Dr. Falk Pharma GmbH today announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease.

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food & Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for the potential expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to

U.S. Food and Drug Administration Accepts Takeda's Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

OSAKA, Japan, & GENEVA, Switzerland--(BUSINESS WIRE)--As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries' healthcare systems to meet patients' need for plasma and plasma-derived therapies. The initiative will draw on UNITAR's expertise

Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies

Zoetis

TAK vs. ZTS: Which Stock Is the Better Value Option?

TAK vs. ZTS: Which Stock Should Value Investors Buy Now?

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Enel North America today announced the signing of a long-term virtual power purchase agreement (VPPA) for the electricity delivered to the power grid from a 79 megawatt (MW) portion of Enel's Seven Cowboy wind project in the state of Oklahoma in the U.S. The agreement, advised by Edison Energy LLC, advances progress towards achieving Takeda's goals of reducing 40 percent of scopes 1 and 2 greenhouse gas (GHG) emiss

Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cel

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

These stocks both yield more than three times the S&P 500 average.

Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years

Quest Diagnostics

CDPATH supports shared decision-making between patients and healthcare providers; provided at no cost to eligible adult patients who have not yet experienced serious complications* CAMBRIDGE, Mass. , Sept. 14, 2022 /PRNewswire/ -- Takeda ( TSE:4502/NYSE:TAK ) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized prognostic tool that uses blood tests† to help predict the potential risk of developing serious Crohn's disease-related complications within three years.1,2 CDPATH is available for use by US-based physicians and offered at no cost to eligible patients††, providing an opportunity for patients to partner with their physicians to map out a personalized disease management plan.

Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease

Takeda has a stable, reliable core drug portfolio with some new product areas showing promise. Their global reach puts them on par with western pharmaceutical companies, but also presents a headwind for expenses and currency exchange rates.

Takeda: A Lot To Like

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced four new partnerships to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare for people in developing and emerging countries. Even the best clinics and hospitals are unable to offer consistent, appropriate, quality care if people cannot access them; a strong health workforce, sustainable supply chains, appropriate resources, and much more are key to building

Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries

Takeda has a dividend yield of 5.26%. It represents only 28% of free cash flow. Takeda is undervalued by nearly 70%.

Takeda: The Current Price Makes No Sense

NEW HAVEN, Conn.--(BUSINESS WIRE)--Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN), today announced that Teresa Bitetti, President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Ltd., has joined the Board of Directors of Osmol Therapeutics. CIPN affects approximately 80 percent of the estimated 360,000 patients who are treated with taxanes in the U.S. and European

Osmol Therapeutics Announces Appointment of Teresa Bitetti, President, Global Oncology Business Unit at Takeda Pharmaceuticals, to the Board of Directors

The USD-JPY cross has surged to fresh 24-year highs, up more than 30% YoY. The currency move is a benefit from Takeda Pharma, but the stock has not performed well in 2022 despite boasting a big dividend.

Takeda: Benefits From A Falling Yen, But Shares Stuck In A Downtrend

TAK or ZTS: Which Is the Better Value Stock Right Now?

Bayer AG

Enel SpA

LM Ericsson Telefon

Sirius XM Holdings Inc

Universal Technical Institute

Vale S.A.

Generally speaking, you want to focus your investments on companies with strong fundamentals, not just on companies that meet a certain price metric, such as stocks under $15. However, certain public firms offer compelling narratives that patient buyers can hold for the long run.

7 Stocks Under $15 to Buy and Hold Forever

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the company's dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), for the prevention of dengue disease caused by any serotype in individuals six years to 45 years of age. The use of QDENGA should be in accordance with official recommendations. QDENGA is the only

Takeda's QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 2022 Results Conference Call July 28, 2022 6:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andy Plump - President, R&D Costa Saroukos - CFO Masato Iwasaki - Japan General Affairs Conference Call Participants Hidemaru Yamaguchi - Citi Motoya Koutani - Nomura Securities Seiji Wakao - J.P. Morgan Securities Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit Suisse Securities Akinori Ueda - Goldman Sachs Ayako Iwamuro Good evening everybody or good morning everybody.

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript

Japan's Takeda Pharmaceutical Co said on Thursday first-quarter profit slumped 39% percent from a year earlier, when earnings had been boosted by the sale of its diabetes drug portfolio.

Takeda sees quarterly profit drop 39% after last year's one-time gains

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance. The gain on the sale of Takeda's Japan diabetes portfolio in the first quarter of the previous fiscal year has impacted reported financial results on a year-over-year basis, as expected. The sale contributed a one-off 133 billion yen to revenue and 131.4 billion yen t

Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment when used a

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

News for Takeda Pharmaceutical Stock (TAK)